On Friday, Lineage Cell Therapeutics Inc (AMEX: LCTX) opened lower -7.80% from the last session, before settling in for the closing price of $1.41. Price fluctuations for LCTX have ranged from $0.84 to $1.61 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 119.78% annually for the last half of the decade. Company’s average yearly earnings per share was noted 5.56% at the time writing. With a float of $187.49 million, this company’s outstanding shares have now reached $188.53 million.
In an organization with 75 employees, it is important to assess its efficiency.
Lineage Cell Therapeutics Inc (LCTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lineage Cell Therapeutics Inc is 0.55%, while institutional ownership is 48.04%. The most recent insider transaction that took place on Feb 08 ’24, was worth 100,001. In this transaction Director of this company bought 96,155 shares at a rate of $1.04, taking the stock ownership to the 158,801 shares. Before that another transaction happened on Feb 06 ’24, when Company’s Director bought 6,730,770 for $1.04, making the entire transaction worth $7,000,001. This insider now owns 41,666,255 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 46.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.56% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Check out the current performance indicators for Lineage Cell Therapeutics Inc (LCTX). In the past quarter, the stock posted a quick ratio of 2.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.12, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.82 million. That was inferior than the volume of 0.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.18%. Additionally, its Average True Range was 0.12.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 59.67%, which indicates a significant increase from 16.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.84% in the past 14 days, which was lower than the 83.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1965, while its 200-day Moving Average is $1.2103. However, in the short run, Lineage Cell Therapeutics Inc’s stock first resistance to watch stands at $1.3900. Second resistance stands at $1.4800. The third major resistance level sits at $1.5300. If the price goes on to break the first support level at $1.2500, it is likely to go to the next support level at $1.2000. Assuming the price breaks the second support level, the third support level stands at $1.1100.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
There are currently 188,534K shares outstanding in the company with a market cap of 245.09 million. Presently, the company’s annual sales total 8,950 K according to its annual income of -21,490 K. Last quarter, the company’s sales amounted to 2,090 K and its income totaled -4,780 K.
